Pfizer Still Examining Breakup While Analysts See Lower Odds
- CEO Read said that there is no ‘wrong answer’ in decision
- ‘It really doesn’t sound like they’re going to,’ analyst says
This article is for subscribers only.
Five months out from Pfizer Inc.’s self-imposed deadline on whether to break into two separate companies, Chief Executive Officer Ian Read made clear he’s still mulling whether the drug giant is better together or apart.
Read said Tuesday that there’s no “wrong answer” in what’s ultimately chosen and it’s not a “make-or-break” decision. Pfizer could also re-examine a split later on if it initially decides against separating the New York-based company, which has a market valuation of $220 billion.